CAPIVASERTIB RESTRICTS SARS-COV-2 CELLULAR ENTRY: A POTENTIAL CLINICAL APPLICATION FOR COVID-19

Simple item page
dc.contributor.authorSun, Fang
dc.contributor.authorMu, Chenglin
dc.contributor.authorKwok, Hang Fai
dc.contributor.authorXu, Jiyuan
dc.contributor.authorWu, Yingliang
dc.contributor.authorLiu, Wanhong
dc.contributor.authorSabatier, Jean-Marc
dc.contributor.authorAnnweiler, Cédric
dc.contributor.authorLi, Xugang
dc.contributor.authorCao, Zhijian
dc.contributor.authorXie, Yingqiu
dc.date.accessioned2021-12-21T08:53:42Z
dc.date.available2021-12-21T08:53:42Z
dc.date.issued2021
dc.description.abstractCoronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic eraen_US
dc.identifier.citationSun, F., Mu, C., Kwok, H. F., Xu, J., Wu, Y., Liu, W., Sabatier, J. M., Annweiler, C., Li, X., Cao, Z., & Xie, Y. (2021). Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19. International Journal of Biological Sciences, 17(9), 2348–2355. https://doi.org/10.7150/ijbs.57810en_US
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/5943
dc.language.isoenen_US
dc.publisherInternational Journal of Biological Sciencesen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectType of access: Open Accessen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectAKT inhibitoren_US
dc.subjectcapivasertiben_US
dc.subjectantiviral activityen_US
dc.titleCAPIVASERTIB RESTRICTS SARS-COV-2 CELLULAR ENTRY: A POTENTIAL CLINICAL APPLICATION FOR COVID-19en_US
dc.typeArticleen_US
workflow.import.sourcescience

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Capivasertib restricts SARS-CoV-2.pdf
Size:
1.83 MB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6.28 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Articles